Abstract
Introduction
In vivo imaging enables researchers to view biological processes at the
molecular level. In vivo molecular imaging techniques have important
implications for drug discovery and development because they aid in validating
drug targets and in studying the biodistribution, target binding, clinical
effects, and toxicity of drug candidates.
Get the Answers You Need to Shape Your Strategy
The development of in vivo molecular imaging techniques has important
implications for drug discovery and development. How will pharmaceutical
companies use this valuable information to accelerate their drug development
process? Which imaging companies are the major players in this fi eld?
The FDA has introduced a new exploratory investigational new drug (eIND)
mechanism that encourages companies to use imaging techniques during
early-stage microdosing studies. How can pharmaceutical companies best
capitalize on this new mechanism? Which imaging technologies are likely to see
increased use as the result of eIND? The high cost of in vivo molecular
imaging poses a signifi cant barrier to its widespread adoption. Will
pharmaceutical and biotech companies decide to invest in these technologies
despite the cost or will they seek other options?
The development of combined PET-MRI instrumentation will be a major
breakthrough. How close to market are these powerful new tools? What new
benefi ts will they offer?
Scope
- Factors fueling the molecular imaging market: trend toward systems
biology and personalized medicine, FDA Critical Path initiative, and eINDs.
- In vivo imaging technologies: computed tomography (CT), positron
emission tomography (PET), single photon emission CT (SPECT), magnetic
resonance imaging (MRI), functional MRI, optical
- imaging, and the use of model organisms.
- Imaging initiatives: a review of important new imaging initiatives
related to biomarkers, Alzheimer's disease, lung cancer, and osteoarthritis.
- Applications of imaging to key therapeutic areas: a discussion of
applications in cancer, the brain, and central nervous system disorders.
- Corporate profiles: features on key players in this growing fi eld.
- Outlook for molecular imaging: our take on how the role of
molecular imaging in drug development will evolve over the next several years.
Mentioned in This Spectrum Report-Companies
- Affi body
- Agfa HealthCare
- Alerion Biomedical
- Amersham
- ART Advanced Research Technologies
- Biospace Med
- Bristol-Myers Squibb
- Bruker Biospin
- Caliper Life Sciences
- Cardinal Health
- CTI Molecular Imaging
- Eastman Kodak Health Group
- Eisai
- Elan
- Epix Pharmaceuticals
- Fujifi lm Medical Systems USA
- Gamma Medica-Ideas
- GE Healthcare
- General Electric
- GlaxoSmithKline
- Hamamatsu
- iCAD
- Insight NeuroImaging Systems
- Invitrogen
- Ixico
- Johnson & Johnson
- Kereos
- Kodak
- Li-Cor Biosystems
- Eli Lilly
- MDS Nordion
- Merck
- MIR Preclinical Services
- Molecular Insight Pharmaceuticals
- Novartis
- Pfi zer
- Philips Medical Systems
- Regional Nuclear Pharmaceuticals
- Riverain
- Roche
- SA Instruments
- Siemens Medical Solutions
- Stentor
- Varian Instruments
- VisEn Medical
- Wyeth
- Xenogen
- Zecotek
- Zygogen
View Cart
